Description
Insulin Glargine 100units/ml. 3 ml. 1 Pen. Sold by Shwe Myittar Pharmacy.
Composition and Indication
Lantus is prescribed for individuals with Type 1 or Type 2 diabetes. It contains a long-acting basal insulin glargine. Its purpose is to maintain stable blood sugar levels between meals, serving as a background insulin that operates behind the scenes to regulate glucose throughout the day. Each milliliter of Lantus has 100 units of insulin glargine. One pen contains 3 milliliters which is equal to 300 units of insulin glargine.
Dosage and Precautions
Lantus is a clear solution that should be administered once daily. It is advisable to select a specific time of day that works best for you and consistently inject Lantus at that same time every day.
Recommended starting dosage for type 1 diabetes:
- Begin with Lantus at around one-third of the total daily insulin requirements.
- Use short-acting insulin before meals to meet the remaining insulin needs.
Recommended starting dosage for type 2 diabetes:
- For individuals with type 2 diabetes who are not currently on insulin treatment, start with 0.2 units/kg or up to 10 units of Lantus once daily.
Pay attention to special warnings and precautions, including the risks of hypoglycemia (low blood sugar), hyperglycemia (high blood sugar), skin and subcutaneous tissue disorders, kidney and liver diseases and potential interactions with other medications (Thiazolidinediones).
Undesirable Effects and Drug Interactions
While using Lantus, you may experience certain side effects. These can include hypoglycemia (low blood sugar), skin changes at injection sites, skin and allergic reactions at injection site and allergic reactions/
It's important to be aware of the potential for interactions with other medications. Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics. GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors may cause hypoglycemia (low blood sugar). Dosage reductions and increased frequency of glucose monitoring may be required when LANTUS is co-administered with these drugs.
Whereas atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones may cause hyperglycemia (high blood sugar). Dosage increases and increased frequency of glucose monitoring may be required when LANTUS is coadministered with these drugs.
Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Beta-blockers, clonidine, guanethidine, and reserpine can potentially diminish or completely mask the initial warning signs that help you recognize low blood sugar levels.
Storage
For unused Lantus SoloStar pen, store them in a refrigerator between 2°C and 8°C, ensuring they are not placed in or too close to the freezer section or cooling element.
While using the Lantus SoloStar pen, avoid returning it to the refrigerator and refrain from storing it in an environment exceeding 30ºC. It's best to keep the pen away from direct light and sources of heat.
Once you begin using your Lantus SoloStar, it can be utilized for a period of 28 days. It is important to discard the pen after this timeframe, even if there is still some insulin remaining inside.
For More Information
Common Health offers customers free access to telemedicine care with general medicine doctors trained on managing non-communicable diseases like diabetes. If you have questions about Lantus or other medications used to treat diabetes, please contact us via phone, Facebook, or Viber to arrange a free consultation.
The information above was sourced from Sanofi, the manufacturer of the product. It was verified by Dr. Khine Khine Zaw in May 2023.
Description
Insulin Glargine 100units/ml. 3 ml. 1 Pen. Sold by Shwe Myittar Pharmacy.
Composition and Indication
Lantus is prescribed for individuals with Type 1 or Type 2 diabetes. It contains a long-acting basal insulin glargine. Its purpose is to maintain stable blood sugar levels between meals, serving as a background insulin that operates behind the scenes to regulate glucose throughout the day. Each milliliter of Lantus has 100 units of insulin glargine. One pen contains 3 milliliters which is equal to 300 units of insulin glargine.
Dosage and Precautions
Lantus is a clear solution that should be administered once daily. It is advisable to select a specific time of day that works best for you and consistently inject Lantus at that same time every day.
Recommended starting dosage for type 1 diabetes:
- Begin with Lantus at around one-third of the total daily insulin requirements.
- Use short-acting insulin before meals to meet the remaining insulin needs.
Recommended starting dosage for type 2 diabetes:
- For individuals with type 2 diabetes who are not currently on insulin treatment, start with 0.2 units/kg or up to 10 units of Lantus once daily.
Pay attention to special warnings and precautions, including the risks of hypoglycemia (low blood sugar), hyperglycemia (high blood sugar), skin and subcutaneous tissue disorders, kidney and liver diseases and potential interactions with other medications (Thiazolidinediones).
Undesirable Effects and Drug Interactions
While using Lantus, you may experience certain side effects. These can include hypoglycemia (low blood sugar), skin changes at injection sites, skin and allergic reactions at injection site and allergic reactions/
It's important to be aware of the potential for interactions with other medications. Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics. GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors may cause hypoglycemia (low blood sugar). Dosage reductions and increased frequency of glucose monitoring may be required when LANTUS is co-administered with these drugs.
Whereas atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones may cause hyperglycemia (high blood sugar). Dosage increases and increased frequency of glucose monitoring may be required when LANTUS is coadministered with these drugs.
Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Beta-blockers, clonidine, guanethidine, and reserpine can potentially diminish or completely mask the initial warning signs that help you recognize low blood sugar levels.
Storage
For unused Lantus SoloStar pen, store them in a refrigerator between 2°C and 8°C, ensuring they are not placed in or too close to the freezer section or cooling element.
While using the Lantus SoloStar pen, avoid returning it to the refrigerator and refrain from storing it in an environment exceeding 30ºC. It's best to keep the pen away from direct light and sources of heat.
Once you begin using your Lantus SoloStar, it can be utilized for a period of 28 days. It is important to discard the pen after this timeframe, even if there is still some insulin remaining inside.
For More Information
Common Health offers customers free access to telemedicine care with general medicine doctors trained on managing non-communicable diseases like diabetes. If you have questions about Lantus or other medications used to treat diabetes, please contact us via phone, Facebook, or Viber to arrange a free consultation.
The information above was sourced from Sanofi, the manufacturer of the product. It was verified by Dr. Khine Khine Zaw in May 2023.